Trial Profile
A phase I study of vaccination with NY-ESO-1 protein mixed with Hiltonol, Picibanil and Montanide in patients with cancers expressing NY-ESO-1 antigen
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 May 2017
Price :
$35
*
At a glance
- Drugs Cancer vaccine NY-ESO-1 (Primary) ; Montanide ISA-51 (Primary) ; Picibanil (Primary) ; Poly ICLC (Primary)
- Indications Cancer; Gastric cancer; Lung cancer; Malignant melanoma; Oesophageal cancer
- Focus Adverse reactions
- 19 May 2017 Status changed from active, no longer recruiting to completed.
- 24 May 2012 New trial record